Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32550898)

  • 1. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
    Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
    Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
    [No Abstract]   [Full Text] [Related]  

  • 2. pH-Responsive PEG-Shedding and Targeting Peptide-Modified Nanoparticles for Dual-Delivery of Irinotecan and microRNA to Enhance Tumor-Specific Therapy.
    Juang V; Chang CH; Wang CS; Wang HE; Lo YL
    Small; 2019 Dec; 15(49):e1903296. PubMed ID: 31709707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
    Lo YL; Lin HC; Tseng WH
    Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression.
    Wang CS; Chang CH; Tzeng TY; Lin AM; Lo YL
    Nanoscale Horiz; 2021 Sep; 6(9):729-743. PubMed ID: 34323910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting.
    Tang B; Zaro JL; Shen Y; Chen Q; Yu Y; Sun P; Wang Y; Shen WC; Tu J; Sun C
    J Control Release; 2018 Jun; 279():147-156. PubMed ID: 29653223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
    Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
    J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
    Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
    Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
    Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
    Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
    Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
    Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
    Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy.
    Chen S; Rong L; Lei Q; Cao PX; Qin SY; Zheng DW; Jia HZ; Zhu JY; Cheng SX; Zhuo RX; Zhang XZ
    Biomaterials; 2016 Jan; 77():149-63. PubMed ID: 26599622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
    Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
    Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloprotein-triggered, cell penetrating peptide-modified star-shaped nanoparticles for tumor targeting and cancer therapy.
    Guo F; Fu Q; Zhou K; Jin C; Wu W; Ji X; Yan Q; Yang Q; Wu D; Li A; Yang G
    J Nanobiotechnology; 2020 Mar; 18(1):48. PubMed ID: 32183823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
    Gao W; Xiang B; Meng TT; Liu F; Qi XR
    Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
    Liu Y; Wu X; Gao Y; Zhang J; Zhang D; Gu S; Zhu G; Liu G; Li X
    Int J Nanomedicine; 2016; 11():3891-905. PubMed ID: 27574422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid-Induced Activated Cell-Penetrating Peptide-Modified Cholesterol-Conjugated Polyoxyethylene Sorbitol Oleate Mixed Micelles for pH-Triggered Drug Release and Efficient Brain Tumor Targeting Based on a Charge Reversal Mechanism.
    Tian Y; Mi G; Chen Q; Chaurasiya B; Li Y; Shi D; Zhang Y; Webster TJ; Sun C; Shen Y
    ACS Appl Mater Interfaces; 2018 Dec; 10(50):43411-43428. PubMed ID: 30508486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-Sensitive nanoparticles as smart carriers for selective intracellular drug delivery to tumor.
    Li XX; Chen J; Shen JM; Zhuang R; Zhang SQ; Zhu ZY; Ma JB
    Int J Pharm; 2018 Jul; 545(1-2):274-285. PubMed ID: 29733971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
    Yu DH; Lu Q; Xie J; Fang C; Chen HZ
    Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.